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Abstract
A natural product chemistry-based approach was applied to discover small-molecule inhibitors of
hypoxia-inducible factor-1 (HIF-1). A Petrosaspongia mycofijiensis marine sponge extract yielded
mycothiazole (1), a solid tumor selective compound with no known mechanism for its cell linedependent cytotoxic activity. Compound 1 inhibited hypoxic HIF-1 signaling in tumor cells (IC50
1 nM) that correlated with the suppression of hypoxia-stimulated tumor angiogenesis in vitro.
However, 1 exhibited pronounced neurotoxicity in vitro. Mechanistic studies revealed that 1
selectively suppresses mitochondrial respiration at Complex I (NADH-ubiquinone
oxidoreductase). Unlike rotenone, MPP+, annonaceous acetogenins, piericidin A, and other
Complex I inhibitors, mycothiazole is a mixed polyketide/peptide-derived compound with a
central thiazole moiety. The exquisite potency and structural novelty of 1 suggest that it may serve
as a valuable molecular probe for mitochondrial biology and HIF-mediated hypoxic signaling.
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1. Introduction
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Marine natural products have emerged as a rich source of chemical diversity for drug
discovery, especially in the area of molecular-targeted anticancer chemotherapeutics.1,2
Mycothiazole (1) belongs to a structurally distinct class of mixed polyketide synthase/nonribosomal peptide synthase (PKS-NRPS)-derived natural products that contain a thiazole
ring embedded between two acyclic polyketide chains.3 Mycothiazole was first isolated
from the marine sponge Spongia mycofijiensis4 [subsequently reclassified as Cacospongia
mycofijiensis5,6 Kakou, Crews, & Bakus (Thorectidae)], and later reported to exhibit tumor
cell line-dependent cytotoxicity in the National Cancer Institute (NCI) 60-cell line screen.7
The structural uniqueness and pharmacological activity of 1 have inspired numerous projects
aimed at its total synthesis.7–15 However, the E-configuration at the C-14/C-15 double
bond of 1 has recently been revised to Z,3 and no report has appeared describing the total
synthesis of this revised scaffold. Furthermore, the molecular target(s) affected by 1 and the
mechanism(s) of action for 1 to suppress tumor cells have remained unknown.

2. Results and discussion
2.1. Compound acquisition and HIF-1 inhibitory activity
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Mycothiazole (1) was obtained during our campaign to discover natural product-derived
small molecule HIF-1 inhibitors. A key regulator of oxygen homeostasis, HIF-1 mediates
cellular adaptation to hypoxia by activating the expression of genes that increase oxygen
availability and those that decrease oxygen consumption.16 Extensive laboratory and
clinical studies indicate that the dysregulation of HIF-1 contributes to both the etiology and
progression of cancer .16 Preclinical studies revealed that HIF-1 inhibition reduces tumor
growth/progression and enhances treatment outcome when combined with radiation and
chemotherapeutic agents.16 Over 15,000 extracts of marine invertebrates and algae (NCI's
Open Repository) were evaluated in a human breast tumor T47D cell-based reporter assay
for HIF-1 inhibitory activity.17 An active lipid extract of the marine sponge Petrosaspongia
mycofijiensis inhibited hypoxia (1% O2)-induced HIF-1 activation by 97% (5.0 μg/mL).
Bioassay-guided isolation followed by dereplication-based structure elucidation of 1
employed data from a combination of 1H and 13C NMR spectroscopy and ESI mass
spectrometry. Mycothiazole and two structurally related compounds [8-Oacetylmycothiazole (2) and 4,19-dihydroxy-4,19-dihydromycothiazole (3)] were evaluated
in a T47D cell-based reporter assay to determine their effects on HIF-1 activation.
Compound 1 blocked hypoxia-induced HIF-1 activation at single-digit nanomolar
concentrations (Fig. 1A). In contrast, 1 did not inhibit chemical hypoxia (10 μM 1,10phenanthroline)-activated HIF-1 at concentrations up to 10 μM (data not shown). Compound
2 exhibited similar HIF-1 inhibitory activity and selectivity as observed for 1 (Fig. 1A).
Compound 3 was at least 1,000 times less potent than the other two compounds at
suppressing hypoxia-induced HIF-1 activation (Fig. 1A).
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2.2. Suppression of HIF-1 target gene expresssion
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The effects of 1 and analogues on the hypoxic induction of HIF-1 target genes VEGF
(vascular endothelial growth factor) and GLUT-1 (glucose transporter-1) were examined by
real time RT-PCR. In T47D cells, hypoxic exposure (1% O2, 16 h) increased the expression
of VEGF (Fig. 1B) and GLUT-1 (Fig. 1C) at the mRNA level. Compounds 1 and 2 both
suppressed the hypoxic induction of HIF-1 target genes in a concentration-dependent
manner. In contrast, 3 (0.1 μM) did not inhibit the induction of either VEGF or GLUT-1
mRNAs. The effects exerted by these three compounds on the hypoxic induction of
endogenous HIF-1 target genes mirror the response observed in the cell-based HIF-1
reporter assay (Fig. 1A).
2.3. Inhibition of hypoxia-induced angiogenesis
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Hypoxia represents an important stimulus for tumor angiogenesis. One of the mechanisms
employed by hypoxic tumor cells to promote angiogenesis is through the HIF-1-dependent
induction of VEGF, a potent angiogenic factor.18 Agents that inhibit VEGF are in clinical
use for cancer.18 In T47D cells, both hypoxic exposure (1% O2, 16 h) and iron chelator
treatment (10 μM 1,10-phenanthroline, 16 h) significantly increased the production of
secreted VEGF protein, relative to the untreated control (Fig. 2A). Compound 1 selectively
suppressed the induction of secreted VEGF protein by hypoxia, relative to its effect on 1,10phenanthroline-induced VEGF (Fig. 2A). To assess the anti-angiogenic potential of 1, a
human umbilical vein endothelial cell (HUVEC)-based tube formation assay was employed
as an in vitro model. In the absence of angiogenic signals, HUVEC cells appear scattered
(Fig. 2B.a). Addition of angiogenic factors (e.g., recombinant human VEGF protein)
stimulated HUVEC cells to form interconnected tube-like structures (tube formation).19
Normoxic T47D cell-conditioned media also induced tube formation (Fig. 2B.b). Hypoxic
exposure (1% O2, 16 h) significantly enhanced the angiogenic activity of the T47D cellconditioned media sample (Fig. 2B.d), most likely through increased production of
angiogenic factors such as VEGF. At the concentration that inhibited hypoxia-induced
HIF-1 activation and VEGF induction, 1 (10 nM) suppressed the angiogenic activity of the
hypoxic T47D cell-conditioned media (Fig. 2B.e). This inhibitory effect was specific for
hypoxic inducing conditions. Compound 1 did not inhibit the ability of normoxic T47D cellconditioned media to induce angiogenesis (Fig. 2B.c). The observation that 1 did not inhibit
tube formation when added to the hypoxic T47D cell-conditioned media sample (Fig. 2B.f)
suggested that 1 inhibits tumor angiogenesis by blocking the expression of angiogenic
factors, not by directly suppressing the tube formation process. Quantification results (Fig.
2C, tube length; Fig. 2D, number of branching points) corroborate the microscopic
observations (Fig. 2B).
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2.4. Mechanism of action studies
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2.4.1 HIF-1α expression—Discerning the mechanism of action for 1 to inhibit HIF-1
activation involved a multistep process. We first examined the effect of 1 on the induction of
nuclear HIF-1α protein in T47D cells. In general, the induction and activation of the oxygenregulated HIF-1α subunit determines HIF-1 activity.20 Under normoxic conditions, HIF-1α
protein was absent in the nuclear extract sample from control cells (Fig. 3A). Exposure to
hypoxic conditions (1% O2, 4 h) induced the accumulation of nuclear HIF-1α protein (Fig.
3A). While its relative potency was superficially diminished by the short incubation time
course (Western blot 4 hr; pHRE3-TK-Luc reporter assay 16 h), 1 blocked the hypoxic
induction of HIF-1α protein in the nucleus. In contrast, the levels of the constitutively
expressed HIF-1β subunit in the nuclear extract samples were not affected (Fig. 3A).
Compounds that disrupt the mitochondrial electron transport chain (ETC) have been shown
to selectively suppress hypoxia-induced HIF-1 activation.1,21

NIH-PA Author Manuscript
NIH-PA Author Manuscript

2.4.2 Mitochondrial respiration studies—To investigate if 1 inhibits mitochondrial
function, a T47D cell-based respiration study was performed.19 Compound 1 suppressed
oxygen consumption in a concentration-dependent manner (Fig. 3B). The effective
concentrations for 1 to suppress oxygen consumption were within the range of the
concentrations required to inhibit hypoxia-induced HIF-1 activation. Further mechanistic
studies were performed to discern the specific site within the mitochondrial ETC that is
affected by 1. The first study was to investigate if 1 acts as an inhibitor of complex II, III, or
IV of the ETC (Fig. 3C). Addition of a mixture of malate and pyruvate to digitoninpermeabilized T47D cells started respiration by initiating NADH production, thereby
providing a source of electrons for complex I (NADH-ubiquinone oxidoreductase). The
electrons then pass through a series of electron carriers along the ETC to oxygen, the end
electron acceptor. The level of respiration correlates with the rate of oxygen consumption.
Complex I inhibitors such as rotenone (4) suppressed respiration, reflected by a dramatic
decrease in oxygen consumption rate (Fig. 3C). Succinate overcame complex I inhibitorimposed respiration blockade by providing electrons to complex II (succinate-ubiquinone
oxidoreductase) of the respiratory chain. The observation that 1 (10 and 30 nM) failed to
inhibit respiration in the presence of succinate suggests that 1 does not inhibit complex II,
III, or IV (Fig. 3C). In contrast, antimycin A (5) [an inhibitor of complex III (ubiquinolcytochrome c oxidoreductase)] suppressed respiration in the presence of succinate. A
mixture of ascorbate and TMPD (N,N,N’,N’-tetramethyl-p-phenylenediamine) that serves as
an electron source for cytochrome c and hence for complex IV (cytochrome c oxidase)
caused a resumption of respiration that was otherwise blocked at complex III. These
observations suggest that 1 does not affect complexes II, III, or IV of the ETC. To test the
hypothesis that 1 inhibits mitochondrial respiration by selectively targeting complex I, 1 (10
nM) was added to permeabilized T47D cells following the initiation of respiration by a
mixture of malate/pyruvate. Compound 1 suppressed respiration and this inhibition was
subsequently overcome by the complex II substrate succinate (Fig. 3D). These data indicate
that 1 suppresses mitochondrial respiration by selectively inhibiting ETC complex I.
The effects of 1 3 on cellular respiration were further examined in a T47D cell-based
concentration-response study and the data compared to the complex I inhibitor rotenone (4)
(Fig. 3E). Compound 1 is more potent than 4 at suppressing cellular respiration in T47D
cells. Although 1 and 2 exhibited comparable HIF-1 inhibitory activities, 2 was at least 3times less potent. One possible explanation may be that 1 is the active inhibitor and ester
hydrolysis of 2 requires significantly longer cellular incubation than that used for the
respiration studies. As anticipated, the least active HIF-1 inhibitor 3 (30 nM) did not
significantly inhibit cellular respiration.
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2.5. Tumor cell proliferation/viability
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Cell line-dependent growth inhibitory effects were observed when mycothiazole was
examined in the NCI-60 cell line study.4 However, many of the cell lines were insensitive to
1 treatment (GI50 >30 μM, TGI and LC50 >100 μM). The finding that 1 inhibited
mitochondrial respiration at complex I would tend to indicate that the effects of 1 and related
compounds on cell proliferation/viability be reexamined. Standard cytostatic/cytotoxic
assays are generally performed following a 48 h compound treatment/incubation period.
McLaughlin and colleagues reported that an extended exposure time (i.e., 6 d) is required for
mitochondrial inhibitors to suppress cell proliferation/viability.22 Six-day concentrationresponse studies were performed to determine the effects of mycothiazole and the two
analogues on tumor cell proliferation/viability. The inhibitory effects exerted by these
compounds on tumor cell proliferation/viability parallel those observed in the reporter assay
for HIF-1 activity. Compounds 1 and 2 suppressed cell proliferation/viability with
comparable potency, while 3 was at least three orders of magnitude less active (Fig. 4AC).
Among the cell lines examined, T47D cells were the most sensitive and MDA-MB-231 cells
were the least sensitive. The observation that the level of inhibition plateaued at 55% in
T47D cells suggests that only a subpopulation of cells were sensitive to 1 and 2.
2.6. Neurotoxicity assay
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One of the potential side effects associated with the application of mitochondrial inhibitors
is neurotoxicity.22 Primary rat cerebellar granule neurons (CGNs) were used as an in vitro
model for neurotoxicity. Following 24 h compound treatment, the cells were stained with
propidium iodide and Hoechst-33342. Because propidium iodide does not penetrate cell
membranes, it stains only dead cells. Based on morphological characteristics, the cells were
counted and grouped (live versus dead, Fig. 4E; dead neurons - apoptotic, early stage
necrotic, and propidium iodide positive, Fig. 4F). Compound 1 (10 nM, 24 h) treatment
killed all the cells (Fig. 4D and E). Compound 1 was more toxic than the positive control
rotenone that was tested at a ten times higher concentration (Fig. 4D and E). Detachment of
the dead cells contributed to the decrease in the total number of rotenone treated cells (Fig.
4E). Approximately 60% of the attached dead neurons following rotenone treatment
exhibited apoptotic morphology, while 85% of the neurons killed by 1 were late stage
apoptotic/necrotic (Fig. 4F).

3. Conclusion
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Mitochondria consume over 90% of the cellular oxygen through oxidative phosphorylation
to produce ATP. The hypoxia-ROS-HIF model proposes that hypoxia increases
mitochondrial ROS and that the ROS provide a signal that stabilizes HIF-1α protein and
activates HIF-1.21 This study characterized the effects of mycothiazole (1) on HIF-1
signaling pathway and established a probable mechanism of action for the bioactivities
observed for 1. Compound 1 represents the first member of a structurally novel class of
mitochondrial ETC complex I inhibitors. Because of its structural uniqueness, 1 may interact
with the large 45 polypeptide complex I complex at a site different from other natural
product-based [rotenone (4), piericidin (6), annonacin (7), capsaicin (8), etc.] and synthetic
complex I inhibitors [phenoxan (9), fenpyroximate (10), MPP+ (11), and pyridaben (12)].23
The superficial structural resemblance of 1 to the complex III inhibitor myxothiazole (13)
further highlights the novelty of this selective complex I inhibitor as a potentially valuable
molecular probe to investigate mitochondrial function and hypoxic signaling.
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4. Experimental section
4.1 Sponge material, extraction, and isolation

NIH-PA Author Manuscript

The sponge material (C021045) was obtained from the National Cancer Institute’s Open
Repository Program. Petrosaspongia mycofijiensis Bakus (Thorectidae) was collected from
underwater caves (−20 m depth) off the coast of Vanuatu by Dr. Patrick L. Colin (Coral
Reef Research Foundation) on November 18, 2000. The sample was identified by Dr.
Michelle Kelly (National Institute of Water and Atmospheric Research Limited, Auckland,
New Zealand). Marine sponge taxonomy is vibrant and ever changing. Our experience
would indicate that samples of the mycothizole-producing sponge identified as P.
mycofijiensis and the original samples of Cacospongia mycofijiensis are the same species of
sponge found in the waters off Vanuatu. A voucher specimen of the sample used to generate
the extract for the NCI Open Repository was placed on file with the Department of
Invertebrate Zoology, National Museum of Natural History, Smithsonian Institution,
Washington, D.C. The sponge material was frozen at −20 °C, ground in a meat grinder, and
extracted with water. The residual material was lyophilized and extracted with
CH2Cl2:MeOH (1:1), solvents removed under vacuum, and the crude extract stored −20 °C
in the NCI’s Open Repository at the Frederick Cancer Research and Development Center
(Frederick, Maryland). The crude extract (3.0 g) was subjected to bioassay-guided standard
Si gel (200 400 mesh) column chromatography analysis that yielded 1 (41.4 mg). The NMR
spectra were recorded in CDCl3 on Bruker AMX-NMR spectrometers operating at either
400 MHz or 600 MHz for 1H and either 100 MHz or 150 MHz for 13C, respectively. The
NMR spectra were recorded running gradients and residual solvent peaks (δ 7.27 for 1H)
and (δ 77.0 for 13C) were used as internal references. The data matched those of
mycothiazole.3 Compound 2 was obtained by semi-synthesis. A sample of 1 (5 mg, isolated
from C. mycofijiensis) was dissolved in dry pyridine (300 μl) and acetic anhydride (1000 μl).
The mixture was stirred for 24 h and the reaction was quenched with water and extracted
with CH2Cl2. The organic layer was dried with NaSO4 and purified using RP-HPLC
(Phenomenex Luna 5μ, C18 (2), 250 × 10.00 mm, isocratic 70% CH3CN in H2O, 2.0 mL/
min) to generate 2 (1.7 mg). Compound 3 was purified from a 2002 collection of an
individual C. mycofijiensis specimen from Vanuatu (collection no. 02600, 12.7 g wet
weight). The sample was soaked in MeOH (24 h) and partitioned as described previously.3,6
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The CH2Cl2 extract (11.9 mg) was purified using HPLC (10:90→100% CH3CN, 30 min) to
yield pure 1 (3.1 mg) and 3 (1.8 mg). The spectroscopic and spectrometric properties of 1
and 3 were as previously described.3
4.1.1 8-O-Acetylmycothiazole (2)—white oil; [α]24D -7.0 (c 0.1, MeOH); UV (MeOH)
λmax (logε): 233.4 nm (3.7); 1H NMR (CDCl3, 600 MHz) δ 5.83 (1H, ddt, J = 16.2, 10.2,
6.0, H-17), 5.77 (1H, bd, J = 12.2, H-5), 5.72 (1H, dtt, J = 10.2, 7.2, 1.2, H-14), 5.60 (1H,
dtt, J =10.2, 7.8, 1.8, H-15), 5.41 (1H, ddd, J = 11.4, 8.4, 6.0, H-6), 5.30 (1H, dd, J = 10.2,
3.0, H-8), 5.07 (1H, dq, J = 17.4, 1.8, H-18), 5.00 (1H, dq, J = 10.2, 1.8, H-18'), 4.97 (1H,
bs, H-19), 4.80, (1H, bs, H-19'), 3.65 (3H, s, OMe), 3.55 (1H, d, J = 7.2, H-13), 3.24 (1H,
dddd, J = 13.8, 7.2, 6.6, 6.0, H-2), 3.16 (1H, dddd, J = 13.8, 8.4, 6.0, 4.8, H-2), 2.89 (2H,
ddd, J = 7.8, 3.6, 1.8, H-16), 2.48 (1H, dddd, J = 15.0, 10.2, 8.4, 1.2, H-7), 2.35 (1H, m,
H-7'), 2.25 (1H, m, H-3), 2.02 (3H, s, OAc), 1.43, (3H, s, H3-20), 1.42 (3H, s, H3-21); 13C
NMR detected indirectly by HMQC and HMBC (see Supplementary Data) (CDCl3 150
MHz) δ 179.4 (C, C-10), 156.6 (C, C-1), 154.9 (C, C-12), 142.2 (C, C-4), 131.9 (CH, C-5),
129.2 (CH, C-6), 128.4 (CH, C-15), 127.9 (CH, C-14), 125.3 (CH, C-17), 115.9 (CH2,
C-19), 115.2 (CH2, C-18), 112.5 (CH, C-11), 79.4 (CH, C-8), 51.2 (CH3, OMe), 44.5 (C,
C-9), 39.9 (CH2, C-2), 37.1 (CH2, C-3), 31.4 (CH2, C-16), 30.7 (CH2, C-7), 29.4 (CH2,
C-13), 26.1 (CH3, Me-20), 23.9 (CH3, Me-21), 20.9 (CH3, OAc); HRESI-MS [M+Na]+ m/z
469.2123 (calcd for C24H34N2O4NaS, 469.2157).
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4.1.2 Stabilization and formulation—The integrity of 1 was monitored by thin-layer
chromatography (TLC) analysis using Merck Si60F254 plates, visualized after spraying with
a 1% (v/v) anisaldehyde solution in AcOH:H2SO4 (50:1) and subsequent heating. The stock
solution of stabilized 1 contains a mixture of 1 (2 mM) and EDTA (3 mM) in DMSO. In
general, either freshly prepared 1 or the stabilized 1 was used for bioassays.
4.2 Biological studies
4.2.1. Cell culture and cell-based reporter and viability assays—Human breast
tumor T47D cells (ATCC) were maintained in DMEM/F12 media with L-glutamine
(Mediatech), supplemented with 10% (v/v) fetal bovine serum (FBS, Hyclone), 50 units/mL
penicillin and 50 μg/mL streptomycin (Lonza). To monitor HIF-1 activity, a cell-based
luciferase assay employing the pHRE3-TK-Luc reporter was performed as described.17 The
sulfarhodamine B method was used to determine cell viability.19 For the six-day exposure
study, the conditioned media were replaced by fresh culture medium that contains test
compound after three days.
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4.2.2. RNA extraction and quantitative real time RT-PCR—The plating of T47D
cells, compound treatment, extraction of total RNA samples, synthesis of the first strand
cDNAs, gene-specific primer sequences, quantitative real-time PCR reactions, and data
analysis were described.19
4.2.3. ELISA assay for human VEGF protein—The plating of T47D cells, compound
treatments, and ELISA assay for secreted and cellular VEGF proteins were described.17 The
concentration of proteins in the cellular lysate was determined using a micro BCA assay
(PIERCE), and the amount of VEGF protein was normalized to that of proteins in the
cellular lysate.
4.2.4. HUVEC-based tube formation assay—The maintenance of HUVEC cells
(Lonza), collection of T47D cell-conditioned media (CM) samples, the performance and
quantitation of the HUVEC-based in vitro tube formation assay were described previously.
19
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4.2.5. Nuclear extract preparation and western blot analysis—Plating of T47D
cells, compound treatment, and exposure to hypoxic conditions were described.17 Nuclear
extract preparation using NE-PER nuclear and cytoplasmic extraction kit (PIERCE), and
determination of the levels of HIF-1α and HIF-1β proteins in the nuclear extract samples by
western blot were described previously.19
4.2.6. Mitochondria respiration assay—An Oxytherm Clarke-type electrode System
(Hansatech) was used to monitor the rate of oxygen consumption in T47D cells. A nonpermeabilized cell-based respiration assay was performed to determine the effects of
purified compounds on cellular respiration.19 Mechanistic studies were conducted in plasma
membrane permeabilized cells to manipulate the mitochondrial substrates and inhibitors.
Detailed experimental procedures and reagents were the same as those described.19
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4.2.7. Cerebellar granule neuron preparation and neurotoxicity assay—Isolation
and maintenance of cerebellar granule neurons (CGNs) from the cerebella of rat pups (6 7
day old Wistar, Harlan) were performed as described.24 The cells were plated onto
polyethyleneimine-coated LabTek II chamber slides (8-well format, 0.6 × 106 cells per well)
and maintained at 37 °C in a humidified 95% air/5% CO2 environment. Neurotoxicity
assays were conducted in cells that had been in culture for 6 10 days. The cells were
exposed to test compounds at specified concentrations for 24 h. At the end of incubation, the
cells were washed once with buffer A (116 mM NaCl, 25 mM KCl, 20 mM TES, 10 mM
glucose, 1.3 mM CaCl2, 1.3 mM MgCl2, 1.2 mM Na2SO4, 0.4 mM KH2PO4, 0.2 mM
NaHCO3, pH 7.3), and stained for 20 min in buffer A supplemented with 5 μg/mL Hoescht
33342 and 1 μg/mL propidium iodide. The chemicals were purchased from Sigma. The cells
were imaged with an Axiovert 200M epifluorescent microscope and 40x fluar oil objective
(Zeiss). Random fields were imaged so that at least 100 cells per treatment per experiment
were obtained. Propidium iodide positive cells were scored as late stage apoptotic/necrotic.
The propidium iodide-negative cells with condensed and/or fragmented nuclei (as indicated
by Hoescht staining) were scored as apoptotic. The propidium iodide-negative cells with
swelled and fragmented nuclei were scored as early stage necrotic.
4.2.8. Statistical analysis—Data were compared using one-way ANOVA followed by
Bonfferoni post hoc analyses (GraphPad Prism 4). Differences were considered statistically
significant when p < 0.05.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Effects of mycothiazole (1) and mycothiazole analogues (2 and 3) on hypoxia-induced
HIF-1 activation. (A) Concentration-dependent inhibition of hypoxia (1% O2)-induced
HIF-1 activation in a T47D cell-based reporter assay. Compounds 1–3 were tested at the
incrementing concentrations of 0.1, 0.3, 1, 3, 10, 30, 100, and 1000 nM. The protein
synthesis inhibitor cycloheximide (CHX) was tested at 100 μM as a positive control. Data
shown are averages from one representative experiment performed in triplicate and the error
bars indicate standard deviation. (B) Compounds 1 and 2 inhibited hypoxic induction of
VEGF mRNA. T47D cells were exposed to hypoxic conditions (1% O2, 16 h) in the
presence and absence of compounds 1–3. Total RNA samples were isolated from the treated
and untreated cells. The level of VEGF mRNA in each sample was quantified by real time
RT-PCR, normalized to an internal control (18S rRNA), and presented as relative mRNA
level of the normoxic control (“C”). Data shown are averages from two independent
experiments and the error bars represent deviation from the average. (C) Compounds 1 and 2
Bioorg Med Chem. Author manuscript; available in PMC 2011 August 15.
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inhibited hypoxic induction of GLUT-1 mRNA. Experimental design and data interpretation
were the same as those described in (B) except GLUT-1 gene-specific primers were used.
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Figure 2.

Mycothiazole (1) inhibits hypoxic induction of secreted VEGF protein and tumor
angiogenesis in vitro. (A) T47D cells were exposed to hypoxia (1% O2) or 1,10phenanthroline (10 μM) in the presence and absence of 1 for 16 h. Levels of secreted VEGF
protein in the T47D cell-conditioned media samples were determined by ELISA and
normalized to the amounts of cellular proteins. Data shown are average + standard deviation
(N = 3). An asterisk (*) indicates p < 0.05 when compared to the induced control using oneway ANOVA and Bonfferoni post hoc analyses (GraphPad Prism 4). (B) The effects of
T47D cell-conditioned media samples on tumor angiogenesis were evaluated in a HUVECbased tube formation assay. Representative images are shown and each panel includes a 100
μm scale bar. The panels are: a) basal media (negative control); b) normoxic T47D cellBioorg Med Chem. Author manuscript; available in PMC 2011 August 15.
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conditioned media; c) 1 (10 nM) treated normoxic T47D cell-conditioned media; d) hypoxic
T47D cell-conditioned media; e) 1 (10 nM) treated hypoxic T47D cell-conditioned media;
and f) hypoxic T47D cell-conditioned media and 1. (C) Relative tube length in three
randomly selected fields for conditions in Fig. 3B(b e). The data shown are averages and the
error bars indicate standard deviation. An asterisk (*) indicates a statistically significant
difference (p < 0.05) between the hypoxic control and mycothiazole treated hypoxic
samples. (D) Experimental conditions and data presentation are the same as those described
in (C) except the number of branching points was quantified as the tube formation
parameter.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Bioorg Med Chem. Author manuscript; available in PMC 2011 August 15.

Morgan et al.

Page 14

NIH-PA Author Manuscript

Figure 3.
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Mycothiazole inhibits hypoxic induction of nuclear HIF-1α protein and suppresses
mitochondrial respiration at low nanomolar concentrations. (A) Western blot analysis was
performed to determine the levels of HIF-1α and HIF-1β proteins in nuclear extract samples
prepared from T47D cells exposed to hypoxia (1% O2, 4 h) in the presence and absence of
mycothiazole (1). (B) Mycothiazole (1) inhibited oxygen consumption in T47D cells in a
concentration-dependent manner (solid line). Oxygen consumption in control cells is shown
as a dotted line. (C) Compound 1 did not affect mitochondrial ETC complex II, III, or IV.
Substrates and inhibitors were added to digitonin (10 μM)-permeabilized T47D cells at the
specified time point in a sequential manner. (D) Compound 1 inhibited mitochondrial
respiration by targeting complex I. (E) Effects of mycothiazole (1), 8-O-acetylmycothiazole
(2), and 4,19-dihydroxy-4,19-dihydromycothiazole (3) on T47D cell oxygen consumption.
Compounds 1 (black bar), 2 (gray bar), 3 (striped bar) and a positive control rotenone (4)
(open bar) were tested at the specified concentrations. Data are presented as % Inhibition
relative to the untreated control. Averages from three independent experiments are shown
and the error bars represent standard deviation.
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Figure 4.
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Cell line-dependent growth inhibition and cytotoxicity by mycothiazole and analogues. Six
day concentration-response results of mycothiazole (1), 8-O-acetylmycothiazole (2), and
4,19-dihydroxy-4,19-dihydromycothiazole (3) on the proliferation/viability of T47D (A),
PC-3 (B), and MDA-MB-231 (C) cells. Cell viability was determined using the
sulforhodamine B method and presented as % Inhibition of the untreated control. Data are
averages from one representative experiment performed in triplicate and the error bars
represent standard deviation. (D) Representative images of untreated rat cerebellar granule
neurons (CGNs, control) and those exposed to rotenone (4, 0.1 μM) and 1 (0.01 μM),
stained with Hoescht 33342 and propidium iodide (PI). (E) The extent of cell death in four
randomly selected fields was quantified for each condition in Fig. 5D, according to the
morphologic characteristics defined in the panel to the left. CGNs that exhibited the
characteristics of apoptotic (PI negative, condensed or fragmented nuclei), early stage
necrotic (PI negative, fragmented nuclei, and swelled morphology), necrotic and late stage
apoptotic (PI positive) cells are all considered dead or dying. The PI negative and healthy
cells are grouped as live. Averages from one representative experiment (out of three
experiments) are shown and the bars indicate standard deviation. (F) The dead or dying
CGNs observed in Fig. 5D were grouped as apoptotic, early stage necrotic, and PI positive
(necrotic and late stage apoptotic). Data presentation was the same as described in Fig. 5E.
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